Cell Transplantation
The adult heart lacks repair capabilities and cannot regenerate itself after myocardial injury (Myocardial Infarction, Heart Attack). Thus patients often develop congestive heart failure that may be fatal. Researchers at the Angiogenesis Research Center are investigating the use of autologous cells transplantations to attempt to regenerate the damaged heart. We biospy skeletal muscles (legs) and isolate cells with regenerative potential, allow them to multiply, and then reimplant the cells into areas of damaged myocardium to restore myocardial function. In addition, pleuripotent cstem cells can be used to regenerateheart muscle and specialized cells and cells can be used for the delivery of transgenes to the heart (gene therapy) allowing regulatable gene expression and multigene expression. Most Recently Autologous myotissue transplantation has been studied with remarkable preclinical success.

{short description of image} Ameroid Constrictor model: Angiography shows the metal ameroid constrictor occluding the left circumflex artery. This was a control animal with no filling of the distal vessel via collaterals and severe ischemia of the LCX distribution even at rest. This would ultimately result in transmural myocardial damage and infarction with scar formation. These models can be used to test the regenerative potentials of several treatment startegies including cell transplantation.





{short description of image} Autologous myoblast transplantation was carried out in a canine model of myocardial infarction in an effort to investigate myoblast survival and activity. Shown are histological section showing autologous skeletal myoblast tranplanted successfully in the heart with short term survival






{short description of image} Delivery remains the achilles's heal of many cellular transplantation approaches to angiogenesis and myogenesis. Shown here is Trichrome staining of the needle track produced by intramyocardial delivery emphasizing the fibrosis that results from the trauma and the paucity of transplanted myoblasts that survive that injury




Cell-based gene transfer is a promising new strategy that utilizes autologous cells transfected with a transgene of interest to express that transgene in vivo. The advantage of such a system is to circumvent the inflammatory response by using autologous cells and achieve prolonged expression by stable transfection using various measures including in vitro retroviral or lentiviral transfection. In addition, complex constructs can be performed that would allow stable regulatable expression and multiple transgene expression. To illustrate this delivery modality, endothelial cells were evaluated for their potential use in gene transfer to deliver apolipoprotein E (apoE) in the murine apoE knockout mice. After transplantation of the apoE secreting Pro-175 endothelial cells into apoE-deficient mice, serum cholesterol levels were lower in animals that have received the apoE secreting endothelial cells compared with the levels of age-matched controls having received non-secreting endothelial cells. Concomitant with cholesterol reduction, atherosclerotic aortic plaques were noticeably reduced in the animals receiving apoE secreting endothelial cells. In other studies, cell lines transduced with a retroviral vector containing the human erythropoeitin (hEpo) cDNA driven by the hypoxia-responsive promoter. In vitro, these cells showed a threefold increase in hEpo secretion as oxygen levels were shifted from 21% to 1.3% oxygen. In animals treated with these altered cells, serum hEpo levels in animals exposed to 7% oxygen were two-fold higher than values seen in their control counterparts kept at 21% oxygen.
A discussion of the various delivery vectors would be incomplete without a discussion of the specific needs for the cardiovascular system. Although sustained expression would be desirable for cardiovascular diseases with a specific gene defect such as familial hypercholesterolemia, various dystrophies or Lpa deficiency, transient expression would be preferable for cardiovascular conditions that are self limited such as restenosis after coronary angioplasty. In addition, therapeutic angiogenesis would be best accomplished with a transient expression vector since sustained expression of angiogenic cytokines may lead to pathological angiogenesis.